Tiagabine in the treatment of epilepsy - A clinical review with a guide for the prescribing physician

D. Schmidt, L. Gram, M. Brodie, G. Krämer, E. Perucca, R. Kälviäinen, C. E. Elger

Research output: Contribution to journalArticlepeer-review


Tiagabine is currently recommended mainly as add-on therapy in adults and children above 12 years with partial epilepsy not satisfactorily controlled with other antiepileptic drugs. Based on available evidence and our clinical experience, tiagabine should be used preferably in patients sharing one or more of the following additional features, (i) a history of drug-induced cutaneous adverse events; (ii) mild to moderate epilepsy allowing for a slow titration and gradual onset of anticonvulsant action over a few weeks; (iii) patients for whom it is particularly important to avoid a deterioration in cognitive performance; and, (iv) patients who failed to respond to previous treatment with sodium channel blocker agents as they may particularly benefit from the introduction of tiagabine, due to its GABAergic mechanism of action. Tiagabine can also be used successfully in other patients with refractory partial epilepsy. Tiagabine is not indicated for patients with generalized or unclassified epilepsies and for patients with severely impaired liver function. (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)245-251
Number of pages7
JournalEpilepsy Research
Issue number3
Publication statusPublished - Oct 2 2000


  • Antiepileptic drug
  • Drug evaluation
  • Drug therapy
  • Patient profile
  • Prescribing guide
  • Tiagabine

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology


Dive into the research topics of 'Tiagabine in the treatment of epilepsy - A clinical review with a guide for the prescribing physician'. Together they form a unique fingerprint.

Cite this